The Menlo Park, California-based company plans to demonstrate its sequencing technology on a small genome in the near future.
Dian selected the MassArray system as its platform of choice for molecular genetic testing and will commercialize it and Agena's DNA applications and products.
After three years of work, the EXaCT-1 exome cancer test has become part of clinical cancer care at NewYork-Presbyterian, but developers have higher ambitions.
The company plans to launch the system this summer in Europe, aiming to broaden cell-free DNA screening for trisomy 21, 18, and 13.
The company said that the funds will allow it to take its ReadyPlex rapid blood group genotyping assays into clinical trials and commercialization.
CEO Brad Gray said the firm has outgrown its existing sales model and will be looking to add both new sales leadership and new consumables sales roles.
SMiLE-seq combines antibody arrays, mechanical trapping, and next-generation sequencing readouts to provide a new platform for characterizing DNA-protein interactions.
The funding will support manufacturing of the firm's Idylla PCR-based diagnostics platform and worker training at its Mechelen, Belgium facility.
Frameshift plans to commercialize two applications: one for data quality control and a second for identifying mutations in rare and Mendelian disorders.
Its first client, Haystack Bio, will use Genecloud to analyze and store single-cell genomics data for a proprietary platform it is developing for the immunotherapy market.
The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.
Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.
In Science this week: in vitro generation of human reproductive cells, and more.
Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.